Neuralink CEO Elon Musk expects human trials within six months- Dejkala

It’s been six years since Tesla, SpaceX (and now Twitter) CEO Elon Musk co-founded brain-control interfaces (BCI) startup, Neuralink. It’s been three years since the company first demonstrated its “sewing machine-like” implantation robot, two years since the company stuck its technology into the heads of pigs — and just over 19 months since they did the same to primates, an effort that allegedly killed 15 out of 23 test subjects. After a month-long delay in October, Neuralink held its third “show and tell” event on Wednesday where CEO Elon Musk announced, “we think probably in about six months, we should be able to have a Neuralink installed in a human.”

Neuralink has seen tumultuous times in the previous April 2021 status update: The company’s co-founder, Max Hodak, quietly quit just after that event, though he said was still a “huge cheerleader” for Neuralink’s success. That show of confidence was subsequently shattered this past August after Musk reportedly approached Neuralink’s main rival, Synchron, as an investment opportunity. 

Earlier in February, Neuralink confirmed that monkeys had died during prototype testing of its BCI implants at the ​​University of California, Davis Primate Center but rejected accusations by the Physicians Committee for Responsible Medicine of animal cruelty. In July, Synchron beat Neuralink to market when doctors at Mount Sinai Hospital in New York successfully installed the company’s inch-and-a-half long device into a person living with ALS. The patient, who has lost their ability to move and communicated independently, should be able to surf the web and send text messages using the device to translate their thoughts into computer commands. That same month, an affair Musk had with a Neuralink executive, who is now pregnant with his twins, also came to light. 

Neuralink is still working towards gaining FDA approval for its implant, though the company was awarded the agency’s Breakthrough Device Designation in July 2020. This program allows patients and caregivers more “timely access” to promising treatments and medical devices by fast tracking their development and regulatory testing. As of September, 2022 the FDA has granted that designation to 728 medical devices. 

The FDA has also updated its best practices guidance regarding clinical and nonclinical BCI testing in 2021. “The field of implanted BCI devices is progressing rapidly from fundamental neuroscience discoveries to translational applications and market access,” the agency asserted in its May guidance. “Implanted BCI devices have the potential to bring benefit to people with severe disabilities by increasing their ability to interact with their environment, and consequently, providing new independence in daily life.”

“In many ways it’s like a Fitbit in your skull, with tiny wires,” Musk said of Neuralink’s device during the 2021 livestream event. The device relies on as many as 1,024, 5-micron diameter leads “sewn” into a patient’s grey matter to form connections with the surrounding neurons, providing high-resolution sampling of the brain’s electrical emissions and translating between analog electrical impulses and digital computer code. Theoretically, at least. So far, all Neuralink has accomplished is getting a monkey to play Pong without a joystick.

“We hope to have this in our first humans, which will be people that have severe spinal cord injuries like tetraplegics, quadriplegics, next year, pending FDA [Food and Drug Administration] approval,” Musk told the Wall Street Journal’s CEO Council summit in January. 

Developing…